Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Of taxes and tariffs; the dealing begins; yelling at Yellin; Paul Singer not amused by Bloomberg report; and more!

Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Good morning dealmakers, it’s Obey Martin Manayiti with the US edition of the Wire from the New York newsroom, filling in for ...

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...